| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6978945 | PADAGIS US | Dispensing device |
Jul, 2022
(1 year, 2 months ago) | |
Evamist is owned by Padagis Us.
Evamist contains Estradiol.
Evamist has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Evamist are:
- US6978945
Evamist was authorised for market use on 27 July, 2007.
Evamist is available in spray;transdermal dosage forms.
The generics of Evamist are possible to be released after 31 July, 2022.
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 27 July, 2007
Treatment: NA
Dosage: SPRAY;TRANSDERMAL
More Information on Dosage
EVAMIST family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic